Attovia Posts Q3 Loss of $22.3M With $395.9M Cash and Phase 2 Starts Set for 1H 2027
ATTO sits 23% above its 52-week low of $12.94.
Summary
Attovia reported a $22.3M Q3 net loss with $395.9M in cash, enough to fund operations into 2030, and confirmed two Phase 2 ATTO-1310 trials plus two Phase 1 starts are on track for the first half of 2027.
Key Events · Earnings and Guidance · ATTO
-
Q3 Net Loss Widens to $22.3M
Third-quarter 2026 net loss was $22.3M versus $13.8M a year earlier, driven by R&D of $20.3M (up from $12.3M) and G&A of $4.7M (up from $3.6M).
-
Cash of $395.9M Funds Operations Into 2030
Cash, cash equivalents and marketable securities reached $395.9M at September 30, 2026, up from $152.3M at December 31, 2025, following the August IPO.
-
Two Phase 2 ATTO-1310 Trials Set for 1H 2027
ATTUNE-CPUO targets ~300 patients across 78 sites in North America and the EU; ATTUNE-AD targets ~255 patients across ~60 sites in North America, the EU and Asia-Pacific.
-
Additional Programs Target 1H 2027 Starts
Phase 1 trials for ATTO-2306 and ATTO-1091 are expected to begin in the first half of 2027, and a China Phase 1b in cholestatic pruritus has been initiated with topline expected in 2H 2027.
Analysis · ATTO · Life Sciences
The headline clinical data was already out on November 5, so the incremental news here is financial and operational: a $22.3M quarterly net loss on $20.3M of R&D spend, offset by $395.9M in cash that funds operations into 2030. That runway means no near-term financing need, which matters for a company that only IPO'd in August 2026. The filing also puts concrete shape on the next catalysts — two Phase 2 ATTUNE trials (~300 patients in CPUO, ~255 in high-itch AD) starting in the first half of 2027, plus Phase 1 starts for ATTO-2306 and ATTO-1091 in the same window and a China Phase 1b in cholestatic pruritus with topline in the second half of 2027.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATTO was trading at $15.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $728.6M. The 52-week trading range was $12.94 to $28.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.